# Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants

> **NCT07182656** · PHASE1 · RECRUITING · sponsor: **Yi Fang** · enrollment: 70 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** CIGB-814 (single-dose group)
- **DRUG:** CIGB-814 placebo (single-dose group)
- **DRUG:** CIGB-814 (multiple-dose group)
- **DRUG:** CIGB-814 placebo (multiple-dose group)

## Key facts

- **NCT ID:** NCT07182656
- **Lead sponsor:** Yi Fang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182656, "Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07182656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*